DrugRisk NuvaRing Lawsuit Update: Court Records Show Manufacturer May Have Concealed Dangers

Share Article

The Drug Risk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

Nuvaring lawsuit
Anyone who suffered a blood clot, stroke, DVT or pulmonary embolism after using NuvaRing is urged to contact the DrugRisk Resource Center or speak with a lawyer about their legal rights as soon as possible.

The birth control safety advocates at DrugRisk.com are alerting women who have used the contraceptive NuvaRing of updated legal news on the site showing the maker of the vaginal ring devices may have concealed the risk of dangerous estrogen bursts.

“DrugRisk’s goal is to improve consumer safety by providing the latest drug alerts, research, legal news and recalls. NuvaRing patients have repeatedly asked about the device’s link to blood clots and the status of ongoing injury lawsuits,” explains DrugRisk representative Ryan Mayer.

The resource center has included health expert warnings which link vaginal ring contraceptives like NuvaRing to higher blood clot risks than traditional birth control pills. Last year, the New England Journal of Medicine published a study finding vaginal ring contraceptives could relate to a 2.5 to 3-fold increased risk of blood clots.*

DrugRisk has also compiled the latest figures from the FDA, which show more than 5,300 adverse reports have been filed among women using NuvaRing devices.** The most common side effects were 1,177 occurrences of pulmonary embolism and 1,155 reports of thrombosis or deep vein thrombosis. Over 30% of cases resulted in hospitalization while 3% ended in death.**

So far, nearly 1,100 women have filed a NuvaRing lawsuit over blood clot allegations, which resulted in cases being consolidated to a special federal court in Missouri.*** The formal case is known as In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, Eastern District Missouri.

Now, DrugRisk has learned that a study by Dr. Shelley Ann Tischkau, Ph.D. filed in the court proceedings shows that NuvaRing maker Organon may have concealed the risk of estrogen bursts in test patients to the FDA, which could contribute to the blood clot risks.****

Anyone who suffered a blood clot, stroke, DVT or pulmonary embolism after using NuvaRing is urged to contact the DrugRisk Resource Center or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of federal MDL drug injury cases, DrugRisk only recommends lawyers and law firms who have already handled NuvaRing lawsuits.

For more information on the research, NuvaRing side effects and litigation news related to NuvaRing and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*nejm.org/doi/full/10.1056/NEJMoa1111840
**adverseevents.com/drugdetail.php?AEDrugID=4584&BrandName=NUVARING
***jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_by_District-March-5-2013.pdf
****harrismartin.com/article/15848/mdl-judge-allows-expert-testimony-on-alleged-bursts-in-nuvarings-estrogen-delivery/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patient Advocate
DrugRisk
888-415-1859
Email >
Visit website